Middle East and Africa Drug-Device Combination Market – Industry Trends and Forecast to 2028

Market Analysis and Insights: Middle East and Africa Drug-Device Combination Market

Drug-Device combination market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 8.7% in the forecast period of 2021 to 2028 and is expected to reach USD 1,274.40 million by 2028 from USD 678.90 million in 2020. Increasing demand for medical devices, rising government initiatives are the major drivers which boost the demand of the market in the forecast period.

Increasing prevalence of chronic diseases advancement in technology effectively helps the growth of the drug-device combination market. However, the limitations and complications associated with the drug-device combination products may hamper the future growth of the drug-device combination market. The partnerships and collaborations by major market players act as an opportunity. However, strict regulatory framework act as a challenge for the growth of the drug-device combination market.

The drug-device combination market report provides details of market share, new developments, and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario, contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Middle East and Africa Drug-Device Combination - Market Scope and Market Size

Middle East and Africa drug-device combination market is categorized into four notable segments, which are based on product, application, end user, and distribution channel. 

• On the basis of product, the drug-device combination market is segmented into auto-injector, microneedle patch, digital pill, smart inhaler, drug delivery hydrogels, drug-eluting lens, and others. In 2021, auto-injector holds the highest share in the medical devices market as growing demand for highly advanced and efficient drug-device combination technology for treatment.
• On the basis of application, the drug-device combination market is segmented into orthopedic diseases, respiratory diseases, diabetes, oncology, cardiovascular diseases, and others. In 2021, the orthopedic is expected to dominate the drug-device combination market due to increased potential for technological growth, especially in medical devices and healthcare segments, coupled with the increasing availability of advanced medical aids for prevalent health conditions anticipated to propel further market growth.
• On the basis of end user, the drug-device combination market is segmented into clinics, hospitals, home care settings, ambulatory care centers, and others. In 2021, the clinics are expected to dominate the drug-device combination market because most patients prefer to monitor and take treatment from experts in order to avoid further complications.
• On the basis of distribution channel, the drug-device combination market is segmented into direct tender, retail sales, and others. In 2021, the direct tender is expected to dominate the drug-device combination market due to more availability of hospitals and clinics combined with growing international trade systems.

Drug-Device Combination Market Country Level Analysis

The drug-device combination market is analyzed, and market size information is provided by product, application, end user, and distribution channel.

The countries covered in the drug-devices combination market report are South Africa and Rest of Middle East and Africa.

South Africa is expected to grow with a substantial growth rate in the forecast period of 2021 to 2028 in Middle East and African countries. The government bodies and healthcare organizations are undertaking various programs in this region; consequently, it is anticipated to propel market growth.  

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of the Middle East and Africa brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels are considered while providing forecast analysis of the country data.  

Growing Partnership and Distribution Agreement with Local Players is Creating New Opportunities for Players in the Drug-Device Combination Market 

The drug-device combination market also provides you with a detailed market analysis for every country's growth in the drug-device combination product industry. Additionally, it provides detailed information regarding growing partnership and distribution agreements with local players. The data is available for the historical period 2010 to 2019. 

Competitive Landscape and Market Share Analysis

Drug-Device combination market competitive landscape provides details by a competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width, and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to the drug-device combination market.

The major players covered in the report are Medtronic, Amgen Inc., B.D., Eitan Medical, E3D Elcam Drug Delivery Devices, GlaxoSmithKline plc, Bayer AG, NanoPass, Janssen Pharmaceuticals, Inc.(a subsidiary of Johnson & Johnson Sevices, Inc.), Otsuka America Pharmaceutical, Inc., among other domestic and Middle East and Africa players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many product approvals are also initiated by companies worldwide, which are also accelerating the drug-device combination market.

For instance,  

• In July 2021, Eitan Medical announced the expansion of its business by the opening of the German Head Office. This expansion to Europe increased the support of a growing customer base
• In October 2020, Glaxosmithkline Plc announced that the European Medicines Agency (EMA) had accepted regulatory submissions seeking approval for the use of anti-IL5 biologic Nucala (mepolizumab) in three additional conditions: hypereosinophilic syndrome (HES), chronic rhinosinusitis with nasal polyps (CRSwNP) and eosinophilic granulomatosis with polyangiitis (EGPA). This has increased the company’s revenue, thereby attracted more customers towards their company
• In September 2018, Amgen Inc. received marketing approval from the Japanese Ministry of Health, Labour, and Welfare for Blincyto (blinatumomab). The first line usage of Blincyto (blinatumomab) is to treat relapsed or refractory B-cell acute lymphoblastic leukemia. This approval has accelerated the company's position in the Japanese market

Collaboration, joint ventures, and other strategies by the market player are enhancing the company presence in the drug-device combination market, which also provides benefit for the organization.   

SKU-65748